| Name | Oleoylethanolamide |
| Description | Oleoylethanolamide (N-Oleoylethanolamide) is a high affinity endogenous agonist of PPAR-α. |
| In vitro | In vitro studies showed that OEA inhibited transforming growth factor β1-stimulated HSCs activation through suppressing Smad2/3 phosphorylation, α-SMA expression and myofibroblast transformation. |
| In vivo | Treatment with OEA (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuated the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs).?Gene expression analysis of hepatic tissues indicated that OEA inhibited the expression of α-smooth muscle action (α-SMA) and collagen matrix, fibrosis markers, and genes involved in inflammation and extracellular matrix remodeling. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.14 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble) DMSO : 250 mg/mL (767.98 mM), Sonication is recommended.
|
| Keywords | PPARα | PPAR | Oleoylethanolamide | Human Endogenous Metabolite | EndogenousMetabolite | Endogenous Metabolite |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Formamide | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Natural Product Library | Drug Repurposing Compound Library | Natural Product Library for HTS | Cosmetic Ingredient Compound Library | Human Endogenous Metabolite Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Gut Microbial Metabolite Library | Anti-Cancer Drug Library |